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Abstract
Background: Before 2014 (the year of closure of the two largest needle exchange programs in Hungary, which
halved the number of available syringes in the country despite increased injecting risk practices) no HIV was reportedly
acquired in Hungary among people who inject drugs (PWIDs) who were not also men who had sex with other men
(MSM). In 2014, one and in 2015 two non-MSM PWIDs were newly diagnosed with HIV who supposedly became
infected in Hungary, and both incident HIV cases in 2015 were diagnosed in the AIDS stage. In addition, two new
(albeit supposedly imported) non-MSM PWID cases were also registered in the first three quarters of 2016, one of
which subsequently was diagnosed with and then died of AIDS. At the same time, the prevalence of HCV doubled
among PWIDs (from 24% to 49% in Hungary and from 34% to 61% in Budapest).
Case presentation: The case that we discuss in this paper is a male PWID, who was diagnosed with HIV and
AIDS in May of 2015 and then died of AIDS the next month. His HIV infection status was detected with delay, and
then appeared in the official statistics as an incident PWID HIV case and an incident PWID AIDS case, but not as
an incident PWID AIDS death. No contact tracing followed, even though it would have been relatively easy
considering the circumstances. To our knowledge, no HIV post-exposure protocol exists in hospitals, in case of
HIV exposure due to an eventual needle-stick injury.
Conclusions: Our paper draws attention to recently published HIV and AIDS surveillance data, and shows the
failure of the system. While sounding the alarm based on three newly detected PWID HIV cases in the past 2
years may be premature, there are definitely serious problems in the HIV detection and tracing system among
PWIDs in Hungary.
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Background
Recently released surveillance data in Hungary (a country
with about 10 million inhabitants) show low incidence of
HIV and AIDS (respectively 271 and 43 new cases in 2015
and a cumulative total of 3291 and 897 cases by the third
quarter of 2016) (Fig. 1) [1]. Although only 28 people who
inject drugs (PWIDs) were registered with HIV infection,
the situation relating to PWIDs may be a cause for con-
cern. Before 2014, there were two PWID HIV cases
who were also men who had sex with men (MSM) who
self-reported possibly having become infected in
Hungary sexually, but all 21 other infected PWIDs who
were not MSM confirmedly contracted HIV abroad [2].
However, in 2014 one and in 2015 two new cases of HIV
were reported among PWIDs who – according to surveil-
lance documentation – were infected in Hungary [1]. In
addition, the two new PWID HIV cases in 2015 were iden-
tified in the AIDS stage. No incident PWID AIDS deaths
appeared in the official statistics in 2015. In addition, two
new (albeit supposedly imported) non-MSM PWID cases
were also registered in the first three quarters of 2016, one
of which subsequently was diagnosed with and then died
of AIDS [1]. By presenting one of the cases and the
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surrounding circumstances, the authors will illustrate the
need to reassess the current situation.
Case presentation
A man in his mid-twenties who lived in a small village
not far from Budapest presented in May of 2015 to the
emergency room of a hospital near him with severe fa-
tigue, dizziness and drowsiness that had been ongoing
for week. Based on the incorrect conduction of the heart
he was transferred to the Cardiology Unit, where his
rhythm normalized after the installation of a temporary
pacemaker. The cardiological assessment was negative.
Two days later a cranial magnetic resonance imaging
(MRI) scan was performed, which revealed multifocal
nodules possibly originating from inflammation. Subse-
quently he was transferred to the Intensive Therapy Unit
for further workup and care. His mental status and
neurological exam at that time showed altered con-
sciousness of unclear etiology. He had a temperature of
38.7 °C (101.7 °F). Lumbar puncture revealed high
amounts of total protein in the cerebrospinal fluid. Mi-
croorganisms were not detected from the patient’s blood
cultures. Results of autoimmune tests were negative.
Due to the patient’s partial respiratory failure, purulent
discharge in the airways, and constant fever, a thoracic
computed tomography (CT) scan was performed, which
revealed diffuse nodular infiltrative shadows in each side
of the lungs. The patient’s health deteriorated rapidly, so
mechanical ventilation and antihypotensive treatment
were initiated. Due to rising inflammatory parameters
and a deterioration of consciousness, infective endocar-
ditis or meningitis was suspected; therefore, antimicro-
bial treatment was added. The imaging and the laboratory
tests ruled out the suspected diseases.
As it eventually turned out, his medical history in-
cluded drug use (“herbal weed” and “injecting crystal”).
Therefore, on the third day of his stay, blood samples to
test for HIV were sent to a designated laboratory. The
results of the HIV test, however, had not arrived even by
the 7th day of the patient’s stay, so that day repeated
blood samples to test for HIV were sent to the Immun-
ology Laboratory at Szent László Hospital (this hospital
is the only one in Hungary where people with HIV/AIDS
are treated). On the 8th day a telephone call informed
the patient’s physicians (coauthors on this paper) that
his HIV test was positive, and the patient was immedi-
ately transferred to the Central Intensive Therapy Unit
at Szent László Hospital. There advanced AIDS stage
was diagnosed, along with a high viral load in the cere-
brospinal fluid, and low CD4 percentage. Test results for
opportunistic infections (Toxoplasma, Cryptococcus,
Mycobacterium, EBV, and CMV IgM) were negative. A
four-drug highly active antiretroviral therapy (HAART)
regimen was initiated. Despite a month of treatment, the
patient stayed in a coma, his MRI brain scan progressed,
and he subsequently deceased.
Discussion and conclusions
The prevention of the spread of HIV in Hungary is gov-
erned by regulations of the Hungarian Ministry of
Health (regulation 18/2002. (XII. 28.) and its update of
46/2009. (XII.22.)). This regulation consists of three sec-
tions – compulsory HIV testing, voluntary HIV testing,
and the process of HIV testing – and an appendix. The
section on compulsory testing describes occupational
groups that are regularly exposed to blood and either
semen or vaginal fluids, and resolutions to situations
when they refuse being tested; donations of organs,
blood and maternal milk; registration and care of people
with confirmed HIV infection, keeping in mind data
protection and counselling about infection transmission;
evaluation of infection risk following epidermal injuries
and exposures of health care personnel. The section on
voluntary testing outlines sexual partners of HIV in-
fected people, children of HIV infected mothers, PWIDs,
and certain migrants from third countries as groups
where voluntary testing is recommended. The third sec-
tion on the process of HIV testing specifies certain la-
boratories that are obliged to perform HIV testing, and
how laboratories can be qualified to test for HIV; confi-
dential management of personal data of those tested;
confirmation of HIV testing; and how to care for HIV
infected that were tested anonymously. The appendix
lists up laboratories where HIV testing is performed for
free, and health care providers that are authorized to
care for HIV infected.
This medical case illustrates why there is a problem
with the detection and management of HIV among
PWIDs, including the difficulty of case identification,
delay of diagnosis, and lack of post-exposure prophylaxis
protocol. It is notable that this hospital did not have any
rapid HIV test kits: while we are not aware of any statis-
tics on what proportion of hospitals has rapid HIV kits,
given the rarity of HIV in Hungary, hospitals – including
Fig. 1 HIV and AIDS incidence in Hungary in the general population,
as of December 31, 2015. Data based on surveillance conducted by
the National Center for Epidemiology between 2010 and 2015. Note:
numbers refer to the total number of cases within the country
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this hospital – might not be prepared for such scenarios,
since many of them have never encountered it. As a
matter of fact, none of the physicians that examined or
treated the patient thought about HIV infection at the
beginning, despite the patient’s medical history (he self-
reported injecting drugs), especially because none of the
typical visible AIDS symptoms (or any other visible
symptoms for that matter) were present. Noteworthy
problems in the system were revealed when HIV was fi-
nally suspected. Then, according to the regulation de-
scribed above, blood samples were sent to a designated
laboratory. Not only did this process delay proper diag-
nosis, but a combination of timing and common practice
was also unfortunate: first, the three-day national holiday
weekend following the patient’s hospital admission
added further delays to the processing of the samples,
and second, the laboratory – like all other laboratories
in general – processed all samples in an order of arrival
without differentiating between routine tests and tests
needed for hospital emergencies – like this case. This
was the first failure of the system.
Second, we are unaware of any national HIV post-
exposure prophylaxis protocol – either because it does
not exist, or because health care professionals (including
the authors of this paper) are unaware of it even though
it exists. While other countries have protocols, such as
the compulsory testing of patients whose blood, tissue,
or other body fluids that are potentially infectious got
into contract with the blood or mucous membrane or
non-intact skin of a health care professional and, in case
of a positive HIV (or HCV or HBV) test, the immediate
subsequent initiation of post-exposure prophylaxis to
prevent the transmission of blood-borne viruses to the
health care professional [3]. Given that in an intensive
care setting, where there is often a rush to save lives,
safety protocols are not always completely adhered to,
situations may occur where there is an exposure to
blood-borne infections. If there is no information about
the serostatus of a patient in such a situation, or if test-
ing is impossible or delayed, then post-exposure prophy-
laxis may not be implemented.
The third failure of the system was that after HIV was
verified at the laboratory at Szent László Hospital, after
the patient was transferred there and was diagnosed with
AIDS, and after he died of AIDS, data showed up in the
national HIV/AIDS registry only partially: while he was
registered as incident PWID HIV case and an incident
PWID AIDS case, he was not entered into the system as
an incident PWID AIDS death. Given that HIV has been
very rare in Hungary, especially among PWIDs, we sus-
pect that his death was omitted from among the incident
AIDS deaths most probably because his death certificate
indicated an opportunistic illness as the cause of death
instead of the underlying HIV/AIDS.
The fourth failure of the system is the subsequent lack
of contact tracing. To our knowledge, no epidemio-
logical investigation followed this patient’s identification
as an HIV infected PWID, even though such contact tra-
cing should be common practice, especially where HIV
is either rare or high priority (or both) [4]. As we de-
scribe in the next paragraph, the context for an HIV epi-
demic might be increasingly favorable in Hungary.
Therefore, contact tracing of an incident, domestically
acquired HIV infection should have been conducted as a
priority measure.
Even if the system had performed perfectly, however,
there are some additional issues, namely with data pro-
tection, which are most probably universal. For example,
if the patient had been tested for HIV before and known
that he was infected, it would have been at his own dis-
cretion whether he discloses that to hospital personnel.
If personnel are not prepared for HIV infected patient,
that could be a problem. Since this patient lived in a
small village where there are neither needle exchange
programs nor any other helping programs for high-risk
populations, he had a very low chance of being identified
as HIV infected. Even if he had been, it would have been
confidential information between him and his physician.
This is a useful measure for his protection, but it could
backfire in absence of general precautions in healthcare.
New psychoactive substances (NPS) have since about
2010 dominated the injecting drug scene in Hungary as
heroin and amphetamines have become increasingly
rarely available [5]. The injecting of NPS is associated
with a high number of daily injecting episodes and a
high prevalence of syringe sharing and reuse [2]. The
Drug Prevention Foundation (DPA) opened the first nee-
dle exchange program (NEP) in Hungary in 1994 using a
legal loophole, and by the end of 2014 there were
altogether 31 NEPs operating in 21 cities in the country
[6]. The largest in terms of number of clients, contact,
and syringes distributed were Blue Point and the second
largest was DPA. Despite the increased need for sterile
syringes, however, these two largest NEPs were forced to
close down in 2014 as a result of, among others, a polit-
ically motivated decrease of government funding [6].
The number of available syringes accordingly dropped to
less than half of what it was earlier and the number of
distributed syringes per PWID per year is now lower
than 40% of the minimal value recommended by the
WHO [6]. Therefore, not only was there limited access
to NEPs in Hungary before to begin with, after the clos-
ing of the two largest programs the situation became
even worse. Between 2011 and 2014 the prevalence of
HCV among PWIDs rose from 24% to 49% in Hungary
and from 34% to 61% in the capital city of Budapest: a
situation that might be considered as a possible conse-
quence of the closure of the NEPs [7]. Mathematical
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models for HIV and HCV transmission among injecting
drug users delineate that HIV and HCV co-occur in a
way that when the prevalence of HCV is under 35% HIV
prevalence is low, but above this level the probability of
an HIV epidemic increases [8]. This is why the one do-
mestically acquired PWID HIV case in 2014 and the two
cases in 2015 against a prior low number of imported
cases are noteworthy, and raise the question whether
these three HIV infections are isolated exceptions or
whether there is a peat-fire–like hidden HIV epidemic in
the making among PWIDs in Hungary. Moreover, the
occurrence of a domestically acquired triple incident
HIV/AIDS/AIDS death case also suggests that the case
that is presented in this report may be the tip of an
iceberg.
Regular screening of PWIDs for HIV and HCV has oc-
curred through the needle exchange programs around
Hungary, as a collaboration between the National Center
for Epidemiology, the National Focal Point and the NEPs
across the country [9]. The closure of the two largest
NEPs lead to two main consequences. First, not only has
the population that was served by these NEPs become
largely un- or underserved in terms of injecting equip-
ment, but they most probably will fail to participate in
the annual screening campaigns for HIV and HCV. Sec-
ond, since these NEPs served low socio-economic areas
with very high-risk injecting profiles and high prevalence
of HCV [6], the annual screening campaign will most
likely fail to reach high prevalence populations in the
capital, and this selection bias will most likely result in
lower measured prevalence of HCV (and over time HIV)
in Budapest. Therefore, if populations with high inject-
ing risk are excluded from regular screening campaigns,
an eventual HIV outbreak among PWIDs may go largely
undetected.
The patient indicated injecting “crystal”, which is a
common general street name for injectable NPS [5]. As
such, a contact tracing exercise establishing potential
routes of infection transmission should have been not
only necessary because the patient was injecting drugs
against the above described behavioural epidemiological
and risk environment background of drug injecting in
Hungary, but also relatively easy because the patient
lived in a small village not far from Budapest, the capital
of Hungary, where social contacts are highly visible. To
our knowledge, no outbreak investigation or contact tra-
cing followed the discovery of the second case either,
even though that PWID HIV case was also detected in
the AIDS stage. It seems that Hungarian public health
authorities are largely unprepared or maybe even unwill-
ing – as suggested by the government’s moralistic ap-
proach towards drug use – to deal with the reality of
drug injecting related infectious diseases and related
epidemics [2].
Hungary may not be the only country or area where
HIV is currently rare but behavioural epidemiological
and/or risk environmental background factors are such
that more HIV cases might be expected at some future
time. NPS – especially injectable ones – have become
increasingly dominant in countries other than Hungary
as well, such as Romania, Spain, the UK, Poland, Sweden
and Finland [10]. While sounding the alarm based on
three newly detected PWID HIV cases in the past 2
years may be premature, there are some discernible
shortfalls in the HIV detection and tracing system
among PWIDs in Hungary. Therefore, we have the fol-
lowing recommendations. First, it would be useful for
the regulations to include a suggestion for hospitals to
have a designated department or section where rapid
HIV testing is available. Since rapid HIV test kits are
neither prohibitively expensive nor bulky, they should be
readily available in hospitals and clinics, and doctors
should be aware of using them for patients who self-
report behaviours that may put them at risk for HIV in-
fection (especially injecting drugs or being an MSM).
Second, while the regulation contains a paragraph on
post exposure prophylaxis for health care professionals,
having rapid HIV kits available would facilitate compli-
ance. Third, when a person dies as a result of complica-
tions of HIV infection, HIV should be noted as the
primary cause of death. Fourth, while testing of sexual
and injecting contacts of HIV infected people may be
voluntary, it should be compulsory for certain desig-
nated health care professionals to perform contact tra-
cing – an aspect that is currently missing from the
regulation. Therefore, contact tracing should be a prior-
ity, especially because it is a relatively manageable task
due to the low HIV prevalence in the country. In gen-
eral, public health authorities should do the utmost to
monitor, detect and deal with infectious diseases in
countries where there is evidence of substantial increases
in drug injecting and syringe sharing to avoid HIV out-
breaks similar to those in Greece and Romania in 2011
and 2012 [2]. In addition, protocols about post-exposure
prophylaxis should not only exist, but health care
personnel should be aware of them and be able to imple-
ment them. On a population level, harm reduction
should be readily available for those people who engage
in high-risk practices. All this, however, requires suffi-
cient and regularly ongoing financial and moral support
from the respective government and/or sponsoring
entities.
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